

## **Sinfonia Biotherapeutics Selected to Participate at Upcoming Cavendish BioHealth Impact Forum**

*Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences*

**BOULDER, Colorado, April 9, 2019** — Sinfonia Biotherapeutics, an early-stage biotherapeutics company pioneering the development of bioreactor-delivered treatments for inherited and genetically-defined dementia and other neurodegenerative diseases, announced today it has been selected to present at the upcoming Cavendish BioHealth Impact Forum taking place April 11, 2019 in New York, co-hosted with Investnet. The Forum provides an environment for family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish BioHealth Impact Forums are hosted by leading institutions around the United States and take place several times each year.

J. Michael Moffat, Chairman of Cavendish Global explains, “With the help of our expert team, Selection Committee and advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Sinfonia Biotherapeutics’ research and scientific insights in familial dementia and other neurodegenerative diseases positions them to make a major contribution to the treatment of progranulin-related frontotemporal dementia and other genetically-defined neurodegenerative diseases.”

“We are honored to be selected to present at the 2019 New York Forum, and it is further recognition of our innovative approach to treat progranulin-related frontotemporal dementia afflicting thousands of people and families around the world today,” said Bob Blomquist, CEO. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

The Cavendish community consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over \$225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish BioHealth Impact Forum provides impact investors with a curated, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by those actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

**About Sinfonia Biotherapeutics**  
([www.sinfoniabiotherapeutics.com](http://www.sinfoniabiotherapeutics.com))

Sinfonia Biotherapeutics is an early-stage biotherapeutics company developing bioreactor-delivered treatments for familial dementia and other genetically-defined neurodegenerative diseases. There is a huge unmet medical need for effective treatments, yet there are still no drug therapies to halt these diseases. Just as cancer is composed of many different subtypes, we know dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, we are developing biologic therapies that treat familial dementia subtypes with underlying disease mechanisms that are known. Our lead treatment in development is iProg progranulin therapy, our breakthrough treatment to rescue progranulin haploinsufficiency in progranulin-related frontotemporal dementia. IProg is advancing in preclinical studies, and has demonstrated promising preclinical proof of concept results in animals. Sinfonia has the potential to deliver truly life-saving treatments for familial dementia and other genetically-defined neurodegenerative diseases. The company's laboratories are located in Huddinge, Sweden, while the business and finance office is located in Boulder, Colorado, USA.

**For Further information, Contact:**

Bob Blomquist  
CEO, Sinfonia US  
+1 (303) 786-8310

**About Cavendish Global**  
(<http://cavendishglobal.com>)

Cavendish Global is a peer-to-peer community of individually-selected innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace — through connectivity, advisory services, access to key opinion leaders and capital opportunities. The upcoming BioHealth Impact Forum will take place April 11, 2019 at the New York Academy of Sciences, and is by invitation only. Throughout 2019 and early 2020, Cavendish will host Forums in Chicago, Illinois, Phoenix, Arizona, San Francisco, California and additional cities to be announced.

Learn more about the upcoming New York Forum at <http://cavendishglobal.com/2019-nyc/>.

**For Further Information, Contact:**

Ian Kenyon  
Senior Vice President, Cavendish Global  
[Ian.Kenyon@CavendishGlobal.com](mailto:Ian.Kenyon@CavendishGlobal.com)